NR-54001SARS相关冠状病毒2,分离株USA-WA1/2020,重组传染性克隆(icSARS-CoV-2-WT)(病毒)
产品图片

货号/SKU
NR-54001
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、3
产品描述信息
NR-54001??SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Recombinant Infectious Clone (icSARS-CoV-2-WT)(Viruses)|SARS-Related Coronavirus 2|Isolate USA-WA1/2020, Recombinant Infectious Clone (icSARS-CoV-2-WT)|-60°C or colder|RS BaricAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Recombinant Infectious Clone (icSARS-CoV-2-WT), NR-54001.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Note: NR-54001 label lists this clone as wildtype (WT); however, NR-54001 is not WT and includes a T15102A silent mutation.
NR-54001 is an infectious complementary DNA (cDNA) clone of SARS-CoV-2, isolate USA-WA1/2020 created using a reverse genetics system.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Full-length infectious cDNA of SARS-CoV-2 virus, isolate USA-WA1/2020 was generated by cloning seven genomic fragments separately into vector plasmids. A silent mutation (T15102A) to ablate an endogenous SacI site was created in a conserved region of the non-structural protein 12 to distinguish the infectious clone from circulating virus. After assembly into full-length cDNA, full-length RNA was generated and electroporated into Cercopithecus aethiops kidney epithelial cells (Vero E6) to recover icSARS-CoV-2-WT virus. Replication of the recombinant virus icSARS-CoV-2-WT was confirmed, and the virus could be successfully passaged serially in cell culture to titers equivalent to the clinical isolate. The complete genome of recombinant virus icSARS-CoV-2-WT has been sequenced (GenBank: MT461669).
Each vial contains approximately 0.3 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma cells infected with icSARS-CoV-2-WT.
Note: NR-54001 label lists this clone as wildtype (WT); however, NR-54001 is not WT and includes a T15102A silent mutation.
NR-54001 is an infectious complementary DNA (cDNA) clone of SARS-CoV-2, isolate USA-WA1/2020 created using a reverse genetics system.
Note: Genome sequence information is provided on the Certificate of Analysis and includes an analysis of all sequence variations observed for each lot.
Full-length infectious cDNA of SARS-CoV-2 virus, isolate USA-WA1/2020 was generated by cloning seven genomic fragments separately into vector plasmids. A silent mutation (T15102A) to ablate an endogenous SacI site was created in a conserved region of the non-structural protein 12 to distinguish the infectious clone from circulating virus. After assembly into full-length cDNA, full-length RNA was generated and electroporated into Cercopithecus aethiops kidney epithelial cells (Vero E6) to recover icSARS-CoV-2-WT virus. Replication of the recombinant virus icSARS-CoV-2-WT was confirmed, and the virus could be successfully passaged serially in cell culture to titers equivalent to the clinical isolate. The complete genome of recombinant virus icSARS-CoV-2-WT has been sequenced (GenBank: MT461669).
Each vial contains approximately 0.3 mL of spin-clarified cell lysate and supernatant from Homo sapiens lung adenocarcinoma cells infected with icSARS-CoV-2-WT.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送至NIAID进行批准.
注意:nr-54001标签将此克隆列为Wildtype(WT);然而,NR-54001不是WT并且包括T15102A无声突变.
NR-54001是SARS-COV-2的感染性互补DNA(cDNA)克隆,使用反向遗传系统产生的USA-WA1 / 2020.
注意:基因组序列信息在分析证书上提供,并且包括对每个批次观察到的所有序列变化的分析.
SARS-COV-2病毒的全长传染cDNA,通过将七种基因组片段分开克隆到载体质粒中,产生了分离的USA-WA1 / 2020.在非结构蛋白12的保守区域中产生烧蚀内源性SACI位点的沉默突变(T15102A),以区分传染性克隆循环病毒.在组装成全长cDNA之后,产生全长RNA并将其电穿孔进入 mt461669 ).
每个小瓶含有大约0.3ml的旋催化细胞裂解物和来自 Homo sapiens的上清液感染ISSars-CoV-2-WT的肺腺癌细胞.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识

可能感兴趣的内容
2024-10-13
2024-05-19
2021-12-21
2024-05-19
2021-12-21
2020-08-04
2022-04-01
2022-04-01
2023-12-13
2022-04-01
2022-04-01
2022-03-31
2022-04-01
2024-05-19
2021-12-21
2022-04-01
2021-12-21